Wednesday, July 8, 2026

Patent intelligence · US

US 6403771

Method and means for site directed therapy

expired A61KA61K51/1045A61K51/1093
Status expired
Linked drugs 1
Pipeline programs 6
Years to expiry 0
Applicant portfolio 20
Patent details — US 6403771
Jurisdiction
US
Status
expired
Grant date
Jun 11, 2002
Expiration
Jun 6, 2022
Claims
22
CPC classes
A61K, A61K51/1045, A61K51/1093
View on Google Patents ↗

Quick answer

US 6403771 (Method and means for site directed therapy) is held by Actinium Phamaceuticals, Inc.. Status: expired. Granted Jun 11, 2002. Expires Jun 6, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
22
CPC classes
A61K, A61K51/1045, A61K51/1093

More from Actinium Phamaceuticals, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12410249

    Low dose antibody-based methods for treating hematologic malignancies

    Actinium Phamaceuticals, Inc. · Expires Sep 4, 2045

    granted
  2. US 12133849

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeutic

    Actinium Phamaceuticals, Inc. · Expires Oct 31, 2044

    granted
  3. US 12083192

    Methods for treatment of patients with myelodysplastic syndromes

    Actinium Phamaceuticals, Inc. · Expires Sep 5, 2044

    granted
  4. US 11981741

    Humanized anti-CD45 antibodies

    Actinium Phamaceuticals, Inc. · Expires May 9, 2044

    granted
  5. US 11975081

    Bifunctional chelators and conjugates

    Actinium Phamaceuticals, Inc. · Expires May 2, 2044

    granted
  6. US 11964948

    Bifunctional chelators and conjugates

    Actinium Phamaceuticals, Inc. · Expires Apr 18, 2044

    granted
  7. US 11912780

    Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies

    Actinium Phamaceuticals, Inc. · Expires Feb 22, 2044

    granted
  8. US 11844799

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic

    Actinium Phamaceuticals, Inc. · Expires Dec 14, 2043

    granted

Frequently asked questions

What is US patent 6403771?

US 6403771 (Method and means for site directed therapy) is held by Actinium Phamaceuticals, Inc.. Status: expired. Granted Jun 11, 2002. Expires Jun 6, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 6403771?

Actinium Phamaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.

When does US 6403771 expire?

Our index shows an expiration date of Jun 6, 2022 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.